[
  {
    "question": "Pregnant 10 wk of gestation, severe migraine what to give",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "None",
    "subspecialty": "Headache",
    "explanation": "During the first trimester, particularly at 10 weeks gestation, the safety of the fetus is paramount due to the critical period of organogenesis. Many migraine abortive medications carry potential teratogenic risks. Migraine involves abnormal neuronal excitability and activation of central pain pathways. However, the use of drugs that alter these pathways (especially those with teratogenic potential) can adversely affect embryonic development during the first trimester. Although a pregnant patient may experience a severe migraine, the risk of fetal malformation during the critical organ formation period outweighs the benefit of using many migraine-specific abortive pharmacologic agents. The diagnosis is clinical, based on the characteristic headache pattern. Differential diagnoses include tension-type headaches and secondary headache disorders. In early pregnancy, ruling out conditions that may mimic migraine (e.g., hyperemesis gravidarum secondary headaches) is also important. In early pregnancy (first trimester), the conservative approach is preferred. Non-pharmacologic management such as adequate hydration, rest, and stress reduction should be prioritized. Acetaminophen is the only mild analgesic considered safe; however, in severe cases, even though non-pharmacologic measures may be insufficient, many of the common abortive medications (NSAIDs, triptans, ergot derivatives, and many prophylactic agents) either lack sufficient safety data or are contraindicated. Thus, the best approach in this scenario is to avoid specific migraine abortive medications unless absolutely necessary, favoring supportive care. \u2022 Acetaminophen, although safe, is often insufficient for severe migraines. \u2022 NSAIDs are contraindicated in early pregnancy. \u2022 Triptans have limited safety data in the first trimester and are generally avoided unless benefits clearly outweigh risks. \u2022 Ergot derivatives and prophylactic agents like valproate are contraindicated due to teratogenicity. Therefore, the best answer is 'None', meaning no specific migraine medication is recommended at this stage. \u2022 The first trimester is the most sensitive period for fetal teratogenicity.  \u2022 Supportive care remains the cornerstone of migraine management in early pregnancy. Current guidelines emphasize conservative, non-pharmacologic management of migraine in the first trimester. Although mild analgesics like acetaminophen may be used for mild pain, the use of more potent abortive agents is generally deferred unless absolutely necessary due to potential teratogenic risk.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Best anti-emetic medication for migraine",
    "option_a": "(Domperidone): Although a dopamine antagonist, its limited penetration of the blood",
    "option_b": "(Ondansetron): Highly effective in chemotherapy",
    "option_c": "(Metoclopramide): Offers both central anti",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "Anti-emetics are a key component in the management of migraine because nausea and vomiting frequently accompany migraine attacks and can impair the absorption of oral medications. Migraine-associated nausea is mediated partly by the activation of central dopamine receptors as well as other neurotransmitter systems. Metoclopramide, a dopamine D2 receptor antagonist, works by both centrally blocking nausea pathways and peripherally enhancing gastric motility, which is valuable in migraine treatment. Patients with migraine often report nausea that not only contributes to discomfort but also interferes with the ingestion and absorption of oral abortive agents, potentially prolonging the attack. The use of an anti-emetic should be guided by the symptom profile. Differential diagnoses for nausea include gastrointestinal or vestibular causes, but in the context of migraine, it is typically part of the syndrome. For migraine-associated nausea, metoclopramide is considered first-line due to its dual benefit of reducing nausea and improving gastric emptying, thereby enhancing the absorption of concomitant migraine therapies. In pregnancy, metoclopramide is generally considered safe, with caution for potential extrapyramidal side effects. It is also acceptable during lactation with proper monitoring. \u2022 Option A (Domperidone): Although a dopamine antagonist, its limited penetration of the blood\u2013brain barrier decreases its efficacy for centrally mediated nausea in migraine. \u2022 Option B (Ondansetron): Highly effective in chemotherapy-induced nausea due to 5-HT3 receptor blockade, it is less effective in migraine-related nausea where dopaminergic pathways are more involved. \u2022 Option C (Metoclopramide): Offers both central anti-emetic and peripheral prokinetic effects, making it the most effective agent in this scenario. \u2022 Metoclopramide not only alleviates nausea but also accelerates gastric emptying, facilitating better absorption of migraine medications. \u2022 Despite potential extrapyramidal side effects, short-term use in migraine is generally well tolerated. Recent studies and clinical practice guidelines consistently recommend metoclopramide as the first-line agent for migraine-associated nausea. This recommendation is supported by its proven efficacy and acceptable safety profile in both the general population and pregnant patients when used judiciously.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Female with headache, occasional blurring when she lean forward, papilledema only no visual filed defects or VA decrease,, suggestive of IIH what tx",
    "option_a": "Oral prednisone",
    "option_b": "IV methylprednisone",
    "option_c": "Weight loss",
    "option_d": "Optic nerve fenestration",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "Idiopathic Intracranial Hypertension (IIH), also known as pseudotumor cerebri, is characterized by increased intracranial pressure with no identifiable cause. It primarily affects overweight women of childbearing age and is frequently associated with headache and papilledema. The exact pathogenesis of IIH remains unclear, but it is thought to involve impaired cerebrospinal fluid (CSF) absorption, increased CSF production, or cerebral venous outflow abnormalities. The resultant elevated intracranial pressure leads to papilledema and can eventually cause vision loss if untreated. Patients typically present with headache, transient visual obscurations (e.g., blurring when leaning forward), and papilledema on ophthalmologic examination. In this case, the lack of visual field defects or acuity loss suggests early or mild disease. Diagnosis is made based on clinical findings and by excluding other causes of raised intracranial pressure. Neuroimaging (MRI/MRV) is performed to rule out secondary causes such as mass lesions or venous sinus thrombosis. A lumbar puncture confirming an elevated opening pressure (with normal CSF composition) further supports the diagnosis. Weight loss is the cornerstone of management in IIH and is recommended as first-line therapy, especially in patients with mild disease without significant visual deficits. Pharmacologic therapy (e.g., acetazolamide, a carbonic anhydrase inhibitor) is often added if weight loss alone does not sufficiently lower intracranial pressure, particularly in cases with visual deterioration. In pregnant patients, weight loss is advised with nutritional counseling, and acetazolamide can be considered with careful risk\u2013benefit analysis due to potential fetal concerns. \u2022 Option A (Oral prednisone) and Option B (IV methylprednisolone): Steroids may transiently reduce intracranial pressure but are not recommended as first-line therapy due to rebound risk and potential systemic side effects. \u2022 Option D (Optic nerve fenestration): A surgical intervention reserved for patients with progressive visual loss refractory to medical treatment. \u2022 Option C (Weight loss): Is the preferred initial management strategy, particularly in patients with mild or early IIH. \u2022 Weight loss, even a modest reduction in body weight, has been shown to significantly lower intracranial pressure in IIH. \u2022 Close ophthalmologic monitoring is essential to ensure that visual function is preserved. Recent guidelines and studies continue to endorse weight loss as the primary management strategy for IIH. Emerging research emphasizes the benefits of structured lifestyle interventions and early medical therapy in patients at risk for vision loss.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Clear scenario about HC asking about tx",
    "option_a": "Indomethacin",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Hemicrania continua (HC) is a primary headache disorder characterized by a continuous, strictly unilateral headache with superimposed exacerbations. A hallmark of HC is its absolute and dramatic responsiveness to indomethacin, making that drug both a diagnostic and therapeutic tool. The underlying mechanism of hemicrania continua is not fully understood, but it likely involves dysfunction in central pain-modulating pathways including the trigeminal-autonomic circuits and hypothalamic dysregulation. Indomethacin, an NSAID with unique properties, is thought to inhibit prostaglandin synthesis and modulate neural activity in those pathways. Patients typically present with a persistent, unilateral headache that fluctuates in intensity, with exacerbations that may be accompanied by autonomic features. A dramatic, complete resolution of headache upon administration of indomethacin is considered pathognomonic for HC. The diagnosis is clinical and is supported by the absolute response to indomethacin. Differential diagnoses include cluster headache, paroxysmal hemicrania, and chronic migraine. Neuroimaging is usually normal, helping to exclude secondary causes of headache. First-line treatment is indomethacin, which typically leads to complete remission. Alternative agents (e.g., topiramate) may be considered if indomethacin is contraindicated or not tolerated. In the context of pregnancy or lactation, indomethacin is generally avoided especially during the third trimester due to risks such as premature closure of the ductus arteriosus; alternative strategies or careful risk\u2013benefit considerations are needed in these cases. Option A (Indomethacin) is correct. Its unique efficacy in hemicrania continua distinguishes the condition from other unilateral headache disorders. The absence of other options does not detract from the fact that indomethacin is the treatment of choice. \u2022 A complete response to indomethacin confirms the diagnosis of hemicrania continua. \u2022 Always consider HC in patients with continuous unilateral head pain with episodic exacerbations. \u2022 Avoid indomethacin in late pregnancy due to potential fetal risks. Recent guidelines and studies continue to endorse indomethacin as the gold-standard treatment for HC, with ongoing research into alternative therapies for patients who cannot tolerate it. The diagnostic criteria relying on indomethacin responsiveness remain unchanged.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Another scenario of SUNCT (no triggers) what is the tx",
    "option_a": "Lamotrigine",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "SUNCT (Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing) is a rare primary headache disorder classified among the trigeminal autonomic cephalalgias (TACs). Lamotrigine is recognized as a first-line therapeutic option for reducing the frequency and intensity of these brief, severe headache attacks. SUNCT is believed to result from abnormal activation of the posterior hypothalamus and trigeminal pathways, possibly involving sodium channel dysfunction. This neural hyperexcitability leads to the rapid onset of severe, short-duration headache attacks accompanied by prominent cranial autonomic symptoms. Clinically, SUNCT presents with very brief (seconds to minutes) but extremely severe unilateral headache attacks accompanied by ipsilateral autonomic signs such as conjunctival injection and tearing. The absence of identifiable external triggers and the pattern of attacks help distinguish it from other headache types. The differential diagnosis includes other trigeminal autonomic cephalalgias like cluster headache and paroxysmal hemicrania, as well as trigeminal neuralgia. Attack duration, frequency, and associated autonomic features are key to differentiating SUNCT from these entities. Neuroimaging is typically normal. The first-line treatment for SUNCT is lamotrigine, initiated at a low dose and titrated gradually to minimize the risk of adverse effects (e.g., Stevens-Johnson syndrome). Other options include topiramate, gabapentin, and, in refractory cases, therapies like intravenous lidocaine. In pregnancy and lactation, lamotrigine is relatively more acceptable though its dosing may require adjustment due to increased clearance and careful monitoring of serum levels is warranted. Option A (Lamotrigine) is correct. It stands out as the recommended treatment for SUNCT based on its efficacy in reducing attack frequency and severity. Other options, though not listed here, are generally considered secondary or adjunct treatments. \u2022 SUNCT attacks are extremely brief, severe, and typically occur without external triggers. \u2022 Gradual dose escalation of lamotrigine is essential to reduce the risk of serious cutaneous reactions. \u2022 Always monitor for potential drug interactions, especially in women of childbearing age. Recent studies have reaffirmed the efficacy of lamotrigine in SUNCT, with controlled titration protocols enhancing safety. Updated guidelines continue to support lamotrigine as the cornerstone of therapeutic management in SUNCT.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Medication overuse headache is",
    "option_a": "worse when waking up from sleep",
    "option_b": "Mild in intensity",
    "option_c": "Normal MRI",
    "option_d": "???",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "Medication overuse headache (MOH) is a secondary headache disorder that develops as a consequence of the chronic overuse of acute headache medications, leading to a cycle of headache persistence and medication use. Frequent use of headache medications (e.g., triptans, NSAIDs, opioids) leads to adaptations in central pain modulation systems, resulting in sensitization of pain pathways. This maladaptive response perpetuates headache frequency, creating a cycle of overuse and worsening headache. Patients with MOH typically have a history of primary headache disorders (like migraine) who progressively develop daily or near-daily headache attacks. Despite the frequent headaches, neuroimaging studies (such as MRI) are usually normal because MOH is a functional disorder rather than one with structural brain abnormalities. The diagnosis is based on clinical history and the overuse criteria defined in the ICHD-3 (for example, use of simple analgesics on \u226515 days/month or triptans/ergots on \u226510 days/month for over 3 months). Differential diagnoses include chronic migraine, tension-type headache, or secondary headaches due to intracranial pathology, but a normal brain MRI supports the diagnosis of MOH. Management involves the withdrawal of the overused medications \u2013 a process that can be challenging and may temporarily worsen headache symptoms. Preventive therapies for the underlying headache disorder are considered once medication overuse is addressed. In pregnant and lactating patients, careful discontinuation of the overused medication in a controlled setting is advised, along with the use of non-pharmacologic interventions and safe analgesics like acetaminophen where appropriate. Option A (worse when waking up from sleep) and Option B (Mild in intensity) are not typical or defining features of MOH. Option C (Normal MRI) is correct because despite the chronic headache pattern, neuroimaging does not reveal secondary pathology, making it an essential supportive feature in the diagnosis of MOH. \u2022 Always review headache medication use in patients with chronic daily headaches to identify MOH. \u2022 A normal MRI is a key finding that supports the diagnosis, ruling out structural causes. \u2022 Patient education on the risks of medication overuse is vital for long-term management. Recent guidelines emphasize medication withdrawal as the cornerstone of MOH treatment. Research continues to explore optimal strategies for withdrawal and relapse prevention, reaffirming the importance of a normal neuroimaging study in the diagnostic process.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Recurrent attack of 4 days headache followed with ptosis and ophthalmoplegia;",
    "option_a": "Ophthalmoplegic migraine",
    "option_b": "Optic Neuritis",
    "option_c": "Brainstem Migraine",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Ophthalmoplegic migraine is classically described as a headache disorder where episodes of headache are followed by ophthalmoplegia, typically involving the oculomotor (third cranial) nerve. Although originally categorized as a migraine variant, current thinking recognizes it as a recurrent cranial neuropathy. The condition is thought to result from an inflammatory or demyelinating process affecting the cranial nerves, most commonly the oculomotor nerve. This inflammation leads to transient nerve dysfunction causing ptosis and ophthalmoplegia. Recent evidence suggests that the disorder is better classified under recurrent painful ophthalmoplegic neuropathy (RPON). Patients present with recurrent episodes of headache that last several days, followed by the development of ocular motor deficits including ptosis (eyelid drooping) and ophthalmoplegia (impaired eye movements). The temporal sequence of headache followed by nerve palsy is a distinguishing feature. Differentials include brainstem migraine (which usually presents with broader brainstem and cerebellar signs), aneurysmal third nerve palsy, Tolosa-Hunt syndrome, and myasthenia gravis. Neuroimaging (with contrast-enhanced MRI) is essential to rule out structural lesions and may show enhancement of the affected nerve in cases of RPON. Management typically involves the use of corticosteroids to reduce nerve inflammation and support recovery from the ophthalmoplegia. Acute migraine therapies may also be employed as needed. Preventive migraine therapy is considered in recurrent cases. In pregnant or lactating women, corticosteroids can be used with caution after weighing the risks and benefits; non-pharmacologic supportive care is also important. Option A (Ophthalmoplegic migraine) is correct given the classic presentation of headache followed by ptosis and ophthalmoplegia. Option B (Optic Neuritis) would primarily present with visual loss and pain on eye movement without the specific pattern of cranial nerve involvement seen here. Option C (Brainstem Migraine) typically includes additional brainstem symptoms (such as vertigo, dysarthria), making it less consistent with the isolated cranial nerve findings described. \u2022 Always obtain neuroimaging in cases of recurrent ophthalmoplegia to rule out structural causes like aneurysm. \u2022 The condition is now best termed RPON, highlighting its neuropathic rather than purely migrainous nature. \u2022 Corticosteroid therapy is often beneficial during acute episodes. Recent research and updated classifications (ICHD-3) have shifted the view of ophthalmoplegic migraine toward an inflammatory neuropathy model (RPON). Current guidelines advocate for the use of steroids in acute management and emphasize the importance of ruling out secondary causes with imaging.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with migraine headache and white matter changes not typical for MS lesions. What to do:",
    "option_a": "Reassurance",
    "option_b": "IV Methyprednsolone",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Migraine is a primary headache disorder that, in neuroimaging, may sometimes reveal incidental white matter hyperintensities. These changes are often noted on MRI and can be misinterpreted as demyelinating lesions; however, their location, shape, and context differ from those seen in multiple sclerosis (MS). The white matter changes seen in patients with migraine are thought to be related to small vessel ischemic alterations, transient disruptions in perfusion, or neuroinflammatory mechanisms. Unlike the demyelinating plaques of MS, migraine-associated lesions are non-specific and do not signify an ongoing inflammatory process consistent with MS. Patients with migraine frequently undergo neuroimaging when their headache pattern changes or if there are atypical features. When incidental white matter changes are observed, recognizing that they are not typical for MS helps avoid unnecessary treatment or anxiety. The clinical presentation remains that of migraine without features of demyelinating disease. A careful review of MRI characteristics is essential. MS lesions typically are ovoid, periventricular, and oriented perpendicular to the ventricles (Dawson\u2019s fingers). In contrast, migraine-related hyperintensities are often smaller, more punctate, and distributed in a pattern that does not match typical MS changes. Differential diagnoses include small vessel ischemic disease, vasculitis, and rarely MS itself, but clinical context is critical. The appropriate management in these cases is reassurance and continuation of standard migraine therapy. There is no indication for high-dose steroids such as IV methylprednisolone because the imaging findings are benign and not reflective of an active demyelinating process. For pregnant or lactating patients with migraine, treatment approaches should focus on safe abortive and prophylactic medications, with reassurance regarding incidental findings. Option A (Reassurance) is correct because the incidental white matter changes seen in migraine are benign. Option B (IV Methylprednisolone) is inappropriate as it is reserved for acute inflammatory demyelinating events, which are not present in this clinical scenario. 1. Migraine-associated white matter lesions are common and non-specific. 2. Distinguish lesion patterns on MRI to avoid misdiagnosing MS. 3. Reassurance is key when imaging findings align with typical migraine changes. Recent clinical studies and imaging reviews confirm that incidental white matter hyperintensities in migraine patients rarely signify an evolving demyelinating disorder and support a conservative, reassurance-based management approach.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Postpartum via C-section, with headache worse upon standing and Valsalva. Not responding to medication",
    "option_a": "Blood patch",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Post\u2010dural puncture headache (PDPH) is a well\u2010recognized complication following procedures such as epidural or spinal anesthesia. It is characterized by a headache that worsens with upright posture and improves when lying down. The headache arises due to cerebrospinal fluid (CSF) leakage from the puncture site, leading to reduced CSF volume and intracranial hypotension. The resultant downward sagging of the brain triggers traction on pain-sensitive intracranial structures. In postpartum patients, especially after C-section where neuraxial anesthesia is used, PDPH presents as a positional headache that worsens with standing or Valsalva maneuvers. The clinical picture usually includes a pressure-like headache that may be accompanied by neck stiffness or photophobia. The diagnosis is primarily clinical based on the history and headache characteristics. Differential diagnoses include tension-type headache, migraines, and, in rare cases, subarachnoid hemorrhage or meningitis. Distinguished by its postural nature and temporal relationship with dural puncture, PDPH is generally straightforward to identify. The first-line management of PDPH is conservative, including bed rest, hydration, caffeine, and simple analgesics. When symptoms persist and are debilitating, an epidural blood patch is recommended as the next step. For postpartum patients, especially those who are breastfeeding, the blood patch is considered safe and highly effective. Option A (Blood patch) is correct because, in a patient with PDPH not responding to medical therapy, an epidural blood patch is the next appropriate intervention. Other interventions (not listed) may include continued conservative management, but if ineffective, the blood patch remains the standard of care. 1. PDPH is classically postural\u2014worse on standing and better when recumbent. 2. An epidural blood patch has a high success rate in alleviating symptoms. 3. Early recognition and treatment can shorten the duration of symptoms significantly. Recent guidelines and studies support the use of an epidural blood patch in patients with PDPH who do not respond to conservative measures, noting its safety profile in the postpartum and lactating population.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Pediatric Migraine compared to adult",
    "option_a": "Bilateral and shorter",
    "option_b": "Less vomiting",
    "option_c": "Less aura",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Migraines in pediatric patients can differ significantly from those in adults. Recognizing these differences is important for accurate diagnosis and management. In pediatric migraine, the developing brain may process and manifest headache differently. The neural pathways and pain modulatory mechanisms are evolving, which can result in a different presentation compared to adults. Unlike adults, where migraine headaches are often unilateral and prolonged, pediatric migraines are more commonly bilateral and of shorter duration. Children may also have less pronounced auras and a variable presentation of associated symptoms such as nausea and vomiting. The diagnosis of pediatric migraine is based on clinical history and symptom characteristics. Differentials include tension-type headache, cluster headache (less common in children), and other headache disorders. The bilateral presentation and shorter duration are key features that help distinguish pediatric migraine from adult patterns. Management in children involves behavioral modifications, avoidance of known triggers, and symptomatic treatments with medications such as acetaminophen or ibuprofen. Preventive treatments are used when necessary. For pediatric patients, especially when considering pharmacologic therapy, agents must be carefully chosen for safety, with considerations for dosing and potential side effects. Pregnancy and lactation considerations are not applicable for the pediatric population. Option A (Bilateral and shorter) is correct because pediatric migraines typically present as bilateral headaches and tend to have a shorter duration than adult migraines. Other options either incorrectly describe pediatric migraine features or lack supporting evidence. 1. Pediatric migraines are more often bilateral compared to the frequently unilateral nature of adult migraines. 2. The duration of pediatric migraine attacks is usually shorter. 3. Recognizing age-related differences in presentation is crucial for effective management. Recent pediatric neurology guidelines emphasize that pediatric migraine often differs from the adult form in distribution, duration, and associated symptoms, reinforcing the importance of these diagnostic distinctions.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario of nummular headache what is the treatment?",
    "option_a": "Gabapentin",
    "option_b": "Acetaminophen",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Nummular headache is a rare primary headache disorder defined by a localized, coin-shaped area of pain on the scalp. It is a diagnosis of exclusion and is distinct from other primary headache syndromes. The exact mechanism is not fully understood, but it is hypothesized to involve a focal, likely neuropathic process affecting the cutaneous nerves of the scalp. There is no underlying structural lesion found on imaging, and the pain is confined to a specific area. Patients with nummular headache present with a well-circumscribed area of pain that remains constant in size and shape. The pain can be continuous or intermittent and is not usually accompanied by systemic or other neurological symptoms. The presentation makes it distinct from diffuse headache disorders. Diagnosis is primarily based on clinical history and examination. Differential diagnoses include migraine (which is typically not so strictly localized), occipital neuralgia, and scalp conditions such as neuralgias due to local pathology. Neuroimaging is usually normal, helping to rule out other structural causes. There is no universally accepted treatment for nummular headache. However, neuromodulatory agents like gabapentin are commonly used as first-line therapy given the suspected neuropathic etiology. Analgesics such as acetaminophen may provide some symptomatic relief but are generally less effective for this localized, chronic pain. In pregnant or lactating patients, gabapentin is classified as having a relatively favorable safety profile when clearly needed, though benefits must outweigh potential risks and careful monitoring is advised. Option A (Gabapentin) is correct because it is widely used as first-line therapy for nummular headache due to its efficacy in managing neuropathic pain. Option B (Acetaminophen) may help with mild pain but is typically insufficient as a sole treatment for nummular headache. 1. Nummular headache is characterized by a persistent, coin-shaped area of scalp pain. 2. Gabapentin is often the treatment of choice given the likely neuropathic mechanism. 3. A careful evaluation is needed to rule out secondary causes when diagnosing nummular headache. Recent research and expert opinion favor the use of neuromodulators like gabapentin for nummular headache, although large-scale controlled studies are lacking. Current guidelines suggest a trial of such therapy when conservative measures fail.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Female patient post SVD presented with headache, visual field deficit and SIADH (not sure). There are vitals with BP low below 90. What is the diagnosis?",
    "option_a": "Pituitary Apoplexy",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Pituitary apoplexy is an acute clinical syndrome caused by hemorrhage or infarction of the pituitary gland. It most commonly occurs in patients with a previously silent pituitary adenoma or in a setting where the gland is susceptible (for example, during pregnancy when the pituitary enlarges). The condition is characterized by a sudden onset of headache, visual disturbances (often due to compression of the optic chiasm), and endocrine dysfunction. The underlying mechanism involves a sudden hemorrhagic or ischemic event in the pituitary. In pregnancy, pituitary hyperplasia increases the gland\u2019s vascular demands making it more vulnerable to ischemic injury or hemorrhage, especially in states of hypotension. The rapid expansion causes pressure on surrounding structures (leading to visual field deficits) and may impair secretion of anterior pituitary hormones, including ACTH, which can result in acute adrenal insufficiency (hence hypotension). Additionally, disruption of ADH regulation may lead to a picture resembling SIADH. Patients typically present acutely with a severe, sudden headache, often described as the worst headache of their life, along with visual disturbances such as bitemporal hemianopia. Hypotension may signal adrenal insufficiency secondary to pituitary failure. This condition is an endocrine and neurosurgical emergency, and the association with the postpartum period (after a spontaneous vaginal delivery) further supports the diagnosis due to the physiologic enlargement of the pituitary during pregnancy. The differential diagnosis includes subarachnoid hemorrhage, meningitis, and postpartum pituitary infarction (Sheehan syndrome). Neuroimaging with MRI is the modality of choice to visualize hemorrhage or infarction within the pituitary and to assess for mass effect on surrounding structures. Endocrine evaluation with hormone assays (ACTH, cortisol, TSH, etc.) is also critical. Sheehan syndrome, although a postpartum hypopituitarism following significant hemorrhage, typically does not present with acute headache and visual field deficits since the infarcted pituitary often results in gland shrinkage rather than expansion. Immediate management involves stabilizing the patient, including fluid resuscitation and correction of electrolyte imbalances. High-dose IV corticosteroids are recommended to treat potential adrenal insufficiency and reduce inflammation. Urgent MRI is indicated to confirm the diagnosis. Neurosurgical consultation is necessary; surgical decompression may be indicated if there is significant visual impairment or if the patient\u2019s neurological status deteriorates. In pregnant or lactating patients, corticosteroids remain a mainstay of therapy, and imaging protocols are adapted to minimize fetal exposure while still achieving diagnostic clarity. Option A (Pituitary Apoplexy) fits the clinical picture: postpartum state, acute headache, visual field deficits, hypotension (suggesting adrenal insufficiency) and possible SIADH. Other options were not provided, but the described features most directly point to pituitary apoplexy rather than alternative postpartum pituitary disorders such as Sheehan syndrome, which typically lack mass effect symptoms like visual field deficits. \u2022 Acute headache with visual deficits in a postpartum patient should raise suspicion for pituitary apoplexy. \u2022 Hypotension in this setting may be a sign of acute adrenal insufficiency. \u2022 MRI is the key imaging modality for diagnosis. Recent guidelines and reviews emphasize the need for rapid diagnosis with MRI and prompt initiation of high-dose corticosteroids. There is growing evidence supporting early surgical intervention in cases with severe or progressive visual loss to optimize outcomes.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Risk of stroke in Migraine",
    "option_a": "Risk of stroke increased in migraine with aura",
    "option_b": "No increase in stroke risk",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Migraine is a primary headache disorder that can be classified into migraine with aura and migraine without aura. There is a well-established epidemiological association between migraine with aura and an increased risk of ischemic stroke, particularly in young women. The pathophysiological links include cortical spreading depression, which not only precipitates the aura but may also lead to vascular endothelial dysfunction. This dysfunction can promote a prothrombotic state. In addition, factors such as vasospasm and altered cerebral blood flow during the aura phase may contribute to ischemic events. There is also an interplay with other vascular risk factors such as smoking and the use of estrogen-containing medications. Patients with migraine with aura typically exhibit transient neurological symptoms (visual or sensory disturbances) preceding the headache phase. Large population-based and case-control studies have demonstrated that these patients have a modestly increased risk of ischemic stroke, an important consideration in risk stratification especially in women who smoke or use estrogen-containing contraceptives. The diagnosis of migraine with aura is primarily clinical. When evaluating stroke risk in these patients, it is also important to rule out other potential causes of stroke through appropriate neuroimaging. Differential diagnoses include transient ischemic attacks (TIAs) and other secondary headache disorders, which are differentiated by the recurrent, stereotyped nature of migraine auras and the absence of persistent neurological deficits. Management of migraine involves both acute abortive treatment (e.g., NSAIDs, triptans) and prophylactic measures (e.g., beta-blockers, antiepileptics) as needed. For stroke prevention in patients with migraine with aura, risk factor modification is crucial, including smoking cessation and cautious use of estrogen-containing contraceptives. In pregnant and lactating women, non-pharmacological management is preferred when possible, and medications are chosen with caution in light of fetal safety. Option A (Risk of stroke increased in migraine with aura) is correct. Option B (No increase in stroke risk) is incorrect as numerous studies have shown an increased risk, particularly with migraine with aura. Options C and D are not provided. \u2022 Migraine with aura is an independent risk factor for ischemic stroke. \u2022 The risk is particularly relevant in young women with additional vascular risk factors. \u2022 Lifestyle modifications and careful medication selection (especially regarding estrogen use) are essential. Current research and clinical guidelines have reinforced the association between migraine with aura and an increased stroke risk. This has led to more individualized risk factor management, particularly in women of childbearing age, with recent studies focusing on the interplay between migraine, hormonal factors, and stroke risk.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Cluster Headache Treatment in ER",
    "option_a": "Verapamil",
    "option_b": "Sumatriptan",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "Cluster headache is a primary headache disorder classified under the trigeminal autonomic cephalalgias. It is characterized by severe, unilateral, periorbital pain associated with autonomic symptoms such as lacrimation, nasal congestion, and ptosis. Rapid pain resolution is crucial in the emergency setting. The exact etiology of cluster headaches remains unclear, but it is believed to involve the activation of the hypothalamus, which in turn triggers the trigeminal-autonomic reflex pathway. The circadian periodicity commonly seen in cluster headaches is also thought to be linked to hypothalamic dysfunction. Patients present with excruciating, unilateral orbital, supraorbital, or temporal pain lasting from 15 minutes to 3 hours, often accompanied by ipsilateral autonomic signs. The intensity and episodic nature of the pain require rapid intervention, particularly in the emergency department where prompt symptom relief is paramount. The diagnosis of cluster headache is clinical, based on the characteristic pattern of headache attacks and associated autonomic symptoms. Differential diagnoses include paroxysmal hemicrania (which responds to indomethacin), migraine (which typically has a longer duration and is less strictly unilateral), and secondary causes such as intracranial pathology. First-line acute treatment in the emergency setting is high-flow oxygen (100% oxygen at 12 L/min or more) delivered via a non-rebreather mask. Subcutaneous sumatriptan (6 mg) is the next appropriate acute therapy when oxygen alone is insufficient. Verapamil, mentioned in Option A, is used in the prophylactic treatment of cluster headache rather than for abortive therapy. In pregnant or lactating patients, oxygen therapy is safe and preferred, and sumatriptan is used after careful risk-benefit analysis (typically considered if non-pharmacological methods fail). Option B (Sumatriptan) is correct for acute management in the ER due to its rapid onset of action. Option A (Verapamil) is primarily used as a prophylactic agent and is not appropriate for immediate relief during an acute cluster headache attack. Options C and D were not provided. \u2022 High-flow oxygen and subcutaneous sumatriptan are the mainstays of acute cluster headache management. \u2022 Verapamil is reserved for long-term prevention rather than acute treatment. \u2022 Cluster headaches have a circadian pattern and are accompanied by prominent autonomic features. Recent guidelines, including those from the American Headache Society, continue to support the use of subcutaneous sumatriptan and oxygen as effective first-line therapies for acute cluster headache attacks. Ongoing research is exploring the underlying hypothalamic dysfunction in cluster headache to develop more targeted therapies.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Patient was diagnosed with trigeminal neuralgia which of the following will suggest an atypical cause?",
    "option_a": "Old age",
    "option_b": "V1 involvement",
    "option_c": "Abnormal blink reflex",
    "option_d": "Unilateral involvement",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "Trigeminal neuralgia is a neuropathic pain disorder that typically presents as sudden, severe, lancinating pain in the distribution of the trigeminal nerve. The classical form usually affects the maxillary (V2) and mandibular (V3) divisions. Atypical features in the pattern of involvement may suggest a secondary cause. In classical trigeminal neuralgia, demyelination of the trigeminal nerve root (often due to vascular compression) leads to ectopic impulse generation and paroxysmal pain. However, if the ophthalmic division (V1) is involved, it raises concern for an alternative pathology, such as multiple sclerosis, tumors, or other compressive lesions affecting the nerve\u2019s root or its central pathways. Patients with typical trigeminal neuralgia report unilateral, short-lasting, electric shock-like pain in the V2 and V3 distributions with normal neurological examination. Involvement of the V1 distribution is uncommon in idiopathic cases and is considered atypical, prompting further investigation with neuroimaging to rule out secondary causes. Differential diagnoses include secondary trigeminal neuralgia from multiple sclerosis, tumors (such as cerebellopontine angle lesions), or even postherpetic neuralgia. A normal neurological exam is expected in classical cases; hence, abnormal findings such as an abnormal blink reflex (Option C) or involvement of V1 should prompt additional evaluation (typically with MRI) to exclude structural lesions. First-line treatment for classical trigeminal neuralgia is with anticonvulsants such as carbamazepine. In patients who have atypical features (like V1 involvement) or abnormal neurological findings, neuroimaging is essential to evaluate for secondary causes. In pregnant or lactating patients, medication choices require careful risk\u2013benefit analysis; for example, while carbamazepine is effective, it carries teratogenic risks and may require dose adjustments or alternative management in pregnancy. Option A (Old age) is typical for classical trigeminal neuralgia. Option B (V1 involvement) is atypical because classical trigeminal neuralgia most commonly involves V2 and V3 rather than V1, and its involvement should raise suspicion for secondary causes. Option C (Abnormal blink reflex) is also an atypical finding suggesting possible demyelinating pathology; however, among the given choices, V1 involvement is a well-recognized red flag. Option D (Unilateral involvement) is typical, as classical trigeminal neuralgia is usually unilateral. \u2022 Classical trigeminal neuralgia predominantly affects the V2 and V3 divisions; involvement of V1 is a red flag. \u2022 A normal neurological exam is expected in idiopathic cases; any abnormality such as an abnormal blink reflex should prompt further evaluation. \u2022 Neuroimaging (MRI) is indicated in atypical cases to rule out secondary causes like multiple sclerosis or tumors. Recent studies and expert guidelines stress the importance of neuroimaging in trigeminal neuralgia cases that present with atypical features, such as V1 involvement, to exclude secondary causes. Emerging evidence also indicates that detailed neurophysiological testing (including blink reflex studies) may be helpful in differentiating idiopathic from symptomatic cases.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient diagnosed with trigeminal neuralgia, what artery is the cause?",
    "option_a": "Superior Cerebellar",
    "option_b": "Inferior Cerebellar",
    "option_c": "Posterior Cerebellar",
    "option_d": "Posterior communicating",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Trigeminal neuralgia (TN) is a disorder characterized by sudden, severe, brief, stabbing neuropathic facial pain that typically affects one side of the face. The classical form is thought to arise from neurovascular compression at the nerve\u2019s root entry zone. The most accepted mechanism involves chronic pulsatile compression of the trigeminal nerve by a blood vessel \u2013 most commonly the Superior Cerebellar Artery (SCA). This repeated compression leads to focal demyelination at the root entry zone, which in turn produces ectopic nerve impulses and abnormal signal conduction, resulting in the paroxysmal pain attacks seen in TN. High\u2010resolution MRI studies, such as with FIESTA/CISS sequences, have reinforced the link between SCA compression and TN. Patients typically experience sudden, shock-like facial pain triggered by everyday activities (e.g., chewing, talking, light touch). The fact that the SCA loops in close proximity to the trigeminal nerve\u2019s entry zone in the pons correlates well with the typical clinical picture seen in classical TN. Diagnosis is primarily clinical based on the history and nature of pain. Differential diagnoses include atypical facial pain, dental pathology, temporomandibular joint dysfunction, and cluster headache. MRI is used to rule out secondary causes (e.g., tumors or multiple sclerosis) and to visualize neurovascular conflicts. The first\u2010line treatment for classical TN is pharmacologic, most commonly with carbamazepine or oxcarbazepine. For patients who are refractory or unable to tolerate medication, neurosurgical interventions (e.g., microvascular decompression) can be considered. In pregnant or lactating patients, carbamazepine is used with caution due to teratogenic potential, and risks versus benefits must be thoroughly discussed. Option A (Superior Cerebellar Artery) is correct because the SCA\u2019s anatomical course places it in close proximity to the trigeminal nerve root entry zone. Options B (Inferior Cerebellar), C (Posterior Cerebellar), and D (Posterior Communicating) are much less frequently implicated in TN due to their differing anatomical relationships. 1. TN pain is typically triggered by simple stimuli (light touch, chewing). 2. High-resolution MRI studies are crucial to confirm neurovascular compression and rule out secondary causes. 3. The SCA is the vessel most commonly responsible for compressing the trigeminal nerve. Recent imaging studies consistently corroborate the role of the SCA in causing classical TN, and guidelines continue to recommend initial conservative management based on robust evidence from clinical trials and meta-analyses.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Trigeminal neuralgia case what is the most predictive of structural cause?",
    "option_a": "Unilateral",
    "option_b": "old age",
    "option_c": "abnormal blink reflex",
    "option_d": "Involving mainly V1 (?sparin V1)",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "Trigeminal neuralgia most often is of a classical type caused by vascular compression; however, certain clinical findings can indicate a secondary (structural) cause such as a tumor or demyelinating process. Identifying red flags is crucial in guiding further investigations. Structural causes of TN (e.g., tumors, multiple sclerosis plaques) may affect the trigeminal nerve in locations beyond the common vascular compression site. Such lesions can induce changes in nerve conduction and compromise brainstem reflex circuits, leading to an abnormal blink reflex. This objective abnormality reflects disruption of both afferent and efferent pathways in the trigeminal circuit. While typical TN is usually unilateral and involves the maxillary (V2) or mandibular (V3) distributions, abnormal findings in the trigeminal reflexes, such as an abnormal blink reflex, indicate involvement of central pathways. This abnormal reflex is more predictive of a structural lesion underlying the neuralgia (secondary TN). For suspected secondary TN, neuroimaging (preferably high-resolution MRI) is warranted to assess for demyelinating plaques, tumors, or other brainstem lesions. Differentials include classical TN (from vascular compression) versus symptomatic TN (from a structural lesion). An electrophysiological study (blink reflex testing) helps in identifying brainstem pathway dysfunction. When a structural cause is suspected, the primary step is diagnostic imaging to identify the lesion. The treatment is then directed at the underlying cause alongside symptomatic management of pain. While first\u2010line medications (carbamazepine, oxcarbazepine) are used for pain control, addressing the structural abnormality (e.g., using steroids for multiple sclerosis exacerbations or planning for neurosurgical resection for tumors) is critical. In pregnant or lactating patients, the choice of agents must consider teratogenic risks and drug safety profiles. Option A (Unilateral) and Option B (Old age) are common features seen in idiopathic TN and do not specifically indicate a structural lesion. Option D (involving mainly V1) is a red flag but is less objective and less reliably predictive than an abnormal blink reflex, which directly indicates dysfunction of the brainstem circuits. Thus, Option C (Abnormal blink reflex) is the most predictive of an underlying structural cause. 1. An abnormal blink reflex in a TN patient is a red flag for secondary pathology (e.g., multiple sclerosis or tumor). 2. While V1 involvement is atypical for classical TN, objective electrophysiological testing (blink reflex studies) can more reliably indicate structural involvement. 3. Always consider neuroimaging in TN patients with abnormal neurological findings. Recent studies have shown that abnormalities in blink reflex testing correlate strongly with structural lesions affecting the trigeminal pathway. These findings have been supported by updated guidelines recommending early imaging in patients with any atypical or abnormal exam findings.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Most common artery to cause TN?",
    "option_a": "(Superior Cerebellar Artery) is correct due to its known anatomical relationship with the trigeminal nerve. Option B (Anterior Inferior Cerebellar Artery), Option C (Basilar Artery), Option D (Posterior Inferior Cerebellar Artery), and any mention of the Vertebral Artery are less common offenders because of their anatomical courses which do not typically place them adjacent to the trigeminal nerve\u2019s vulnerable entry zone.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "This question reiterates the cause of classical trigeminal neuralgia by asking which artery commonly compresses the trigeminal nerve. The understanding of neurovascular conflicts is central to TN\u2019s pathogenesis. The Superior Cerebellar Artery (SCA) is most often responsible due to its anatomic course near the trigeminal nerve root entry zone. The chronic pulsatile compression from the SCA may lead to focal demyelination of the nerve, resulting in the characteristic paroxysmal pain episodes of TN. Patients with TN typically present with sudden, sharp, and severe facial pain. The proximity of the SCA to the trigeminal nerve explains why vascular loop compression is the most common cause of these symptoms in classical TN. The diagnosis is primarily clinical, but high-resolution MRI (with sequences such as FIESTA) is used to demonstrate the vascular compression. Differential diagnoses include atypical facial pain and symptomatic trigeminal neuralgia due to mass lesions or demyelinating conditions. First-line management is with anticonvulsants such as carbamazepine. If medical management is insufficient, surgical procedures like microvascular decompression may be indicated. In pregnancy or lactation, treatment decisions require careful risk\u2013benefit analysis with consideration of fetal and neonatal safety. Option A (Superior Cerebellar Artery) is correct due to its known anatomical relationship with the trigeminal nerve. Option B (Anterior Inferior Cerebellar Artery), Option C (Basilar Artery), Option D (Posterior Inferior Cerebellar Artery), and any mention of the Vertebral Artery are less common offenders because of their anatomical courses which do not typically place them adjacent to the trigeminal nerve\u2019s vulnerable entry zone. 1. In classical TN, the SCA is the vessel most frequently implicated in neurovascular compression. 2. High-resolution MRI is essential for identifying neurovascular conflicts in TN. 3. Understanding vessel anatomy is key in differentiating the causes of TN. Contemporary surgical and radiological studies support the role of the SCA in causing classical TN. The consistency of these findings across multiple studies has reinforced current guidelines on the diagnosis and management of TN.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient presented with recurrent migraine headache, disabling, causes loss of many hours per week, has history of asthma on inhalers, what is the treatment of choice?",
    "option_a": "Propranolol",
    "option_b": "Primidone",
    "option_c": "Topiramate",
    "option_d": "Amitriptyline",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "Migraine is a common primary headache disorder characterized by recurrent, often unilateral, throbbing headaches typically accompanied by nausea, photophobia, and phonophobia. Prophylactic treatment is indicated for patients with frequent, disabling attacks. Migraine involves complex neurovascular mechanisms, including cortical spreading depression, trigeminovascular system activation, and imbalances in neurotransmitter systems. Genetic, environmental, and hormonal factors also play roles in its pathogenesis. This patient presents with recurrent, disabling migraine headaches that significantly impair daily functioning. The presence of asthma in the patient is clinically important because it influences the choice of prophylactic medication. Migraine is primarily diagnosed based on clinical criteria as outlined by the International Classification of Headache Disorders (ICHD). Differential diagnoses include tension-type headache, cluster headache, and secondary headache disorders. Detailed history and sometimes headache diaries help differentiate these entities. For migraine prophylaxis, first-line medications include beta-blockers (e.g., propranolol), antiepileptics (e.g., topiramate, valproate), and tricyclic antidepressants (e.g., amitriptyline). In this patient, the history of asthma makes non-selective beta-blockers (like propranolol) less appropriate due to the risk of bronchospasm. Topiramate is an established first-line prophylactic agent for migraine and lacks the respiratory contraindications seen with beta-blockers. However, it is important to note that topiramate is teratogenic (associated with cleft lip/palate), so in pregnant or lactating patients or those of childbearing potential, its use requires effective contraception or consideration of alternative agents such as amitriptyline or beta-blockers (if respiratory status permits). Option A (Propranolol) is typically effective for migraine prophylaxis but is contraindicated in asthma due to the risk of precipitating bronchospasm. Option B (Primidone) is used in essential tremor and is not indicated for migraine. Option C (Topiramate) is an effective, FDA-approved migraine prophylactic agent and is the preferred choice in a patient with asthma, though its teratogenic potential must be addressed in women of childbearing potential. Option D (Amitriptyline) is also used for migraine prophylaxis but may be considered second-line in this context. 1. Always consider comorbidities: asthma rules out non-selective beta-blockers like propranolol in migraine prophylaxis. 2. Topiramate is effective for migraine prophylaxis but requires caution in women of childbearing potential due to teratogenic risks. 3. Migraine prophylaxis is indicated when headaches are frequent and significantly impair quality of life. Recent guidelines from headache societies reaffirm topiramate as a first-line treatment for migraine prophylaxis in patients who have contraindications to beta-blockers. Additionally, concerns regarding teratogenicity have led to strong recommendations for counseling and contraception in women of reproductive age using topiramate.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient has migraine headache, tried multiple analgesia and NSAIDs with no benefits, what is the symptomatic treatment?",
    "option_a": "Caffeine with barbiturates",
    "option_b": "Triptans",
    "option_c": "Paracetamol and NSAIDs",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "Migraine is a primary headache disorder characterized by recurrent, often unilateral, throbbing pain accompanied by nausea, photophobia, and phonophobia. When patients do not respond to standard analgesics like NSAIDs or paracetamol, migraine\u2010specific therapies such as triptans are indicated for acute treatment. Migraines involve the activation of the trigeminovascular system with release of vasoactive neuropeptides (eg, CGRP) and subsequent vasodilation. Triptans are serotonin 5-HT1B/1D receptor agonists that cause cranial vasoconstriction and inhibit the release of inflammatory neuropeptides, effectively aborting the migraine attack. Patients typically present with episodic attacks of moderate-to-severe head pain that may be refractory to non-specific analgesics. The lack of response to NSAIDs/pain relievers signals that more targeted therapies, such as triptans, should be considered for symptomatic relief. While the diagnosis of migraine is clinical\u2014using criteria such as those in the ICHD\u2014differentials include tension-type headache, cluster headache, and secondary causes of headache. A thorough history focusing on the duration, associated symptoms, and triggers is key. First-line symptomatic treatment includes NSAIDs for mild-to-moderate attacks; however, for moderate-to-severe or NSAID-refractory migraines, triptans are recommended. In pregnancy, sumatriptan is often preferred after careful risk-benefit assessment. In lactating women, the use of triptans is permitted with appropriate monitoring and counseling. Option A (Caffeine with barbiturates) is not evidence\u2010based for migraine and may lead to medication overuse headache. Option B (Triptans) is correct as they are indicated when standard analgesics fail. Option C (Paracetamol and NSAIDs) have already been trialed by the patient and demonstrated insufficient relief. 1. Triptans are effective for aborting moderate-to-severe migraine attacks. 2. Always assess contraindications to triptan use, particularly cardiovascular risks. Current guidelines, including those from the American Headache Society, support the use of triptans as a second-line option after failure of basic analgesics, with robust evidence for their efficacy and safety when used appropriately in non\u2010contraindicated patients.",
    "exam_year": "2024",
    "exam_type": "Part II"
  }
]